HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (PROCLIVITY 02)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Prometheus Laboratories
Sponsor:
Collaborators:
M.D. Anderson Cancer Center
Johns Hopkins University
Information provided by (Responsible Party):
Prometheus Laboratories
ClinicalTrials.gov Identifier:
NCT01856023
First received: May 10, 2013
Last updated: May 28, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2018
  Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)